SPOA strongly deactivates BCR-ABL1 Y177, preventing GRB2 binding and blocking proliferation, as well as inducing apoptosis in even IM-resistant CML cells [169]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.